The European Commission announced on Wednesday 28 July that it has entered into a joint procurement framework contract with the pharmaceutical company GSK to obtain up to 220,000 doses of sotrovimab (VIR-7831), the candidate treatment for Covid-19 developed by the British company.
This monoclonal antibody-based treatment - developed in collaboration with the American company VIR Biotechnology - had obtained an Emergency Use Authorization (EUA) from the US Food and Drug Administration at the...